Metagenomi Future Growth
Future criteria checks 0/6
Metagenomi's revenue and earnings are forecast to decline at 2.7% and 13% per annum respectively. EPS is expected to grow by 68.9% per annum. Return on equity is forecast to be -31.9% in 3 years.
Key information
-13.0%
Earnings growth rate
68.9%
EPS growth rate
Biotechs earnings growth | 24.5% |
Revenue growth rate | -2.7% |
Future return on equity | -31.9% |
Analyst coverage | Good |
Last updated | 07 May 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 55 | -127 | -58 | -132 | 4 |
12/31/2025 | 38 | -114 | -92 | -70 | 6 |
12/31/2024 | 31 | -100 | -41 | -55 | 7 |
12/31/2023 | 45 | -68 | -101 | -91 | N/A |
9/30/2023 | 38 | -64 | -15 | -3 | N/A |
6/30/2023 | 31 | -54 | -7 | 6 | N/A |
3/31/2023 | 24 | -49 | 4 | 18 | N/A |
12/31/2022 | 17 | -44 | 16 | 30 | N/A |
12/31/2021 | 0 | -21 | 21 | 24 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MGX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MGX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MGX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MGX's revenue is expected to decline over the next 3 years (-2.7% per year).
High Growth Revenue: MGX's revenue is forecast to decline over the next 3 years (-2.7% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MGX is forecast to be unprofitable in 3 years.